Information

15.12.2020

Optimising authorisation-related meetings with applicants

ZL105_00_003e_WL / ZL105_00_004e_FO

01.12.2020

Supplying the population with essential human medicinal products

Swissmedic to provide scientific and regulatory advice free of charge

01.11.2020

Naming of combination partners

Changes to the guidance document Product information for human medicinal products HMV4

01.10.2020

Swissmedic extends the MAGHP procedure

The new Light procedure builds on the established MAGHP procedure, but is explicitly applicable to applications for the fast-track authorisation procedure and for temporary authorisation

18.09.2020

Authorisation of medicinal products for the prevention and treatment of COVID-19

Publication of new guidance document on procedures for authorising medicinal products during a pandemic

18.08.2020

Benchmarking 2020 – Comparison of Swiss approval times for human medicines with the EU and the USA and analysis of national authorisation procedures

Swissmedic compared with the EMA and the FDA and analysis of the national authorisation procedures

01.08.2020

Modification of various documents relating to authorisation

ZL000_00_024e_WL / ZL101_00_007e_WL

03.07.2020

A study confirms Swissmedic’s international Competitiveness

In an international comparison of the processing time for scientific assessments, Swissmedic is on a par with the fastest authorities